查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853299

人类抗菌药物敏感性检测市场（按产品、技术、检测类型、应用、最终用户和病原体划分）—全球预测，2025-2032年

Human Antimicrobial Susceptibility Testing Market by Product, Technology, Test Type, Application, End User, Pathogen - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，人类抗菌药物敏感性测试市场规模将成长 63 亿美元，复合年增长率为 6.10%。

关键市场统计数据
基准年 2024 39.2亿美元
预计年份：2025年 41.6亿美元
预测年份 2032 63亿美元
复合年增长率 (%) 6.10%

本书以强有力的导论形式，概述了正在重塑全球抗菌药物敏感性试验实践的临床、操作和技术因素。

人类抗菌药物敏感性检测领域正曲折点，其驱动因素包括临床需求的汇聚、实验室工作流程的演变以及技术的加速成熟。由于多重抗药性病菌感染、抗药性机制以及对快速有效结果的需求，临床团队面临日益复杂的诊断挑战，这就要求药敏试验结果既可靠又要快速。同时，研发和製药合作伙伴对标准化、可重复的检测平台的需求也在不断增长，这些平台能够整合到药物开发平臺和转换研究中。

实验室面临许多相互衝突的优先事项，包括维持合规性、缩短週转时间以及优化试剂和设备的利用率，同时还要应对预算限制和熟练劳动力短缺的问题。这些营运现实正在重塑采购标准，并将重点转向能够提供自动化、互联互通以及针对不同检体类型检验的效能的系统。先进的分子和表型混合工作流程的采用，正在重新定义药敏试验（AST）的角色，使其成为鑑定和治疗管理之间的桥樑。

在这些压力之下，相关人员必须平衡短期临床需求与长期策略投资。临床医生、微生物学家、资讯科技专业人员和采购团队之间的跨职能协作对于将诊断资讯转化为改善患者预后至关重要。本导言阐述了重要的背景资讯和关键的变革方向，为后续章节的详细分析奠定了基础。

明确技术和商业性转型方向，以加速药敏试验工作流程中的自动化、分子杂合反应和软体整合。

抗菌药物敏感性检测领域正经历着一场变革性的转变，这场变革由自动化、分子整合和软体驱动的决策支援所驱动。自动化系统正逐步减少人工实验室的工作时间和操作差异，使实验室能够在无需相应增加人员的情况下扩大生产能力。这项变革得益于能够整合结果、进行趋势分析并提供以抗菌药物管理为导向的报告的软体平台。

分子检测技术的同步发展使得标靶检测抗药性决定簇成为可能，从而补充了表型药敏试验的结果。结合快速分子筛检和表型确证检测的混合工作流程正在成为兼顾速度和临床相关性的实用解决方案。此外，试剂和耗材的创新，例如预拌培养基、稳定条和试剂套件，正在简化常规工作流程，并提高分散式检测环境中的可重复性。

供应商正优先考虑可互通的平台、开放资料标准以及超越传统资本销售、转向基于耗材和资料主导收入流的服务模式。因此，临床实验室和研究机构必须调整其采购、检验和IT整合方法，才能充分发挥这些创新技术的潜力。

评估2025年生效的美国关税调整对检测采购和实验室连续性的累积营运和供应链影响。

2025年关税措施和贸易政策调整的实施，对参与抗菌药物敏感性测试的实验室、製造商和分销网络产生了复杂的下游影响。关键进口设备、试剂和组件的进口关税增加以及监管摩擦加剧，导致采购前置作业时间延长，并促使采购团队重新评估总到岸成本。因此，供应链规划已从週期性采购转向持续风险规避和多源采购策略。

製造商已采取应对措施，重新评估其全球生产布局，增加受关税影响地区的在地化生产，并重新配置供应链网路以降低成本波动。这些转变改变了库存缓衝、关键耗材策略储备以及与经销商合约条款的决策。对于实验室而言，这些转变也带来了一些实际影响，例如新采购产品的验证期延长、潜在的替代品需要进行交叉验证，以及对供应商服务模式进行严格审查，以确保过渡期间检测能力的持续性。

展望未来，持续的关税主导的供应中断可能会增强区域供应链的韧性，并推动对国内试剂和仪器生产的投资。同时，相关人员应密切注意监管协调工作和贸易谈判，以期缓解摩擦。在此背景下，灵活的筹资策略、加强供应商合作以及前瞻性的验证通讯协定对于维持检测的连续性和临床可靠性至关重要。

透过对产品、技术、测试类型、应用、最终用户和病原体等领域的综合细分洞察，揭示了实际的采购和验证需求。

细緻的细分框架揭示了临床需求、技术能力和采购行为在产品、技术、检测类型、应用、最终用户和病原体等维度上的交集。产品差异化包括仪器、试剂/耗材和软体，其中仪器又细分为桌上型和全自动两种类型，试剂/耗材则细分为光碟、套件、培养基和试纸条。这种产品层面的细分体现在采购优先顺序：桌上型平台通常优先考虑在地化和灵活性，而全自动系统则优先考虑吞吐量和整合性。

技术领域涵盖自动化系统、纸锭扩散法、梯度试纸条法、微量稀释法和分子生物学方法。在自动化系统中，平台层面的差异——MicroScan 型、Phoenix 型和完全整合的 Vitek 型——决定了互通性和实验室工作流程的重新设计。自动化测试和手动测试（手动方法包括琼脂稀释法、肉汤晶粒、纸片扩散法和梯度试纸条法）之间的测试类型差异凸显了分析精度和操作可扩展性之间的权衡。应用范围从临床诊断到药物开发和研究，每种应用场景都对验证的严谨性、可追溯性和数据整合提出了独特的要求。

包括诊所、诊断实验室、医院和研究机构在内的终端用户，各自面临不同的吞吐量需求、资金限制和监管要求，这些因素都会影响产品和技术的采用频谱。病原体分类，例如真菌、革兰氏阴性菌、革兰氏阳性菌和分枝桿菌，以及革兰氏阴性菌的亚分类，例如肠桿菌科和非肠桿菌科，都会影响试剂配方需求、结果判读标准和药敏终点决策。了解这些相互依存的细分层面，有助于相关人员确定投资优先顺序并协调营运蓝图。

关键区域洞察揭示了法律规范、基础设施投资和製造业动态如何影响美洲、欧洲、中东和非洲以及亚太地区的采用。

在美洲、欧洲、中东和非洲以及亚太地区，区域动态正在重塑采购偏好、监管互动以及技术创新的传播。在美洲，对快速诊断的重视以及集中式检测网路的整合，推动了对高通量自动化平台和整合资讯学的需求，以支援相关管理倡议。该地区的实验室越来越注重快速週转和可扩展性，以应对复杂的病例量，这影响着他们对设备和耗材的选择。

欧洲、中东和非洲是一个异质性区域，监管协调工作、公共卫生优先事项和财政限制导致了不同的应用模式。在部分地区，严格的监管路径和集中采购模式有利于采用检验的标准化解决方案。亚太地区在不断扩大的国内生产能力和对实验室基础设施的大力投资的支持下，正迅速采用自动化和分子混合方法。该地区的规模和生产密度也使其成为供应链重组和试剂本地化的重点区域。

在所有地区，当地的法规结构、报销模式和劳动力供应情况将继续影响技术采纳率，并影响供应商的策略。清楚了解每个地区的优先事项至关重要，这有助于制定符合各地区实验室营运和临床管治的市场准入、服务模式和经销伙伴。

分析供应商优先考虑互通性、基于耗材的服务模式和监管合规性的策略，以增强其临床和商业地位。

抗生素敏感性检测生态系统中的主要企业日益重视平台互通性、基于耗材的服务模式以及支持临床决策和抗生素管理目标的数据分析。供应商透过整合与实验室资讯系统的连接、自动化结果解读报告以及提供生命週期服务来增强其价值提案，从而减轻最终用户的检验负担。这些策略倡议优先考虑与临床网络建立长期伙伴关係，而非一次性的仪器销售。

试剂创新，例如稳定试剂套件和简化培养基配方，也正在推动竞争差异化，这些创新能够降低变异性并提高在不同实验室环境下的储存稳定性。製造商正在投资模组化系统，以实现逐步升级，从而在保护资本投资的同时，提高检测通量并扩展检测项目。仪器供应商和分子检测开发人员之间的策略联盟正在加速混合工作流程的发展，从而能够快速将抗药性决定簇的检测结果转化为可操作的药敏性指导。

最后，各公司越来越重视监管合规和本地化支持，他们认识到快速的服务响应和健全的上市后监测对于临床信心至关重要。产品创新、服务导向和监管严格性的结合，塑造了市场的竞争格局，并影响医院、参考实验室和研究机构的采购和伙伴关係选择。

供应商和实验室将提出切实可行的策略建议，以增强其整个药敏试验流程的韧性、互通性和临床影响力。

产业领导者应采取平衡策略，在推进自动化和分子整合的同时，保持对人工操作和分散式检测场景的灵活性。优先投资模组化、可互通的平台，能够帮助实验室在无需巨额资本支出的情况下扩展检测能力。同时，与区域试剂生产商和经销商建立牢固的伙伴关係，可以增强供应韧性，并降低对单一来源供应链的依赖。

在营运层面，将数据分析和以管理为导向的报告融入平台设计，可以提升临床影响力并支持医院管治目标的实现。供应商和实验室都应携手合作，共同规范资料格式，并采用便于与电子健康记录和感染控制系统整合的应用程式介面（API）。从监管和品质角度来看，透过预先核准的方案和统一的方法比较研究来加速验证流程，可以缩短部署时间，并确保在不同环境下效能的一致性。

最后，相关人员应采取动态采购方式，将整体拥有成本、服务应对力和验证负担纳入采购决策。透过将商业模式与临床工作流程和长期支援承诺相结合，行业领导者可以实现永续推广和改善患者预后，同时减少营运和供应链中断。

采用透明的混合方法研究途径，结合文献回顾、主要相关人员访谈和资料交叉检验三角测量，确保分析的严谨性。

调查方法结合了系统性的二手资料收集、有针对性的原始研究以及严谨的资料三角验证，以确保得出可靠且可重复的结论。二手资料收集工作包括对同行评审文献、监管指导文件、技术白皮书和公共采购政策进行结构化审查，以建立关于技术能力、测试标准和监管机构期望的基准事实。这个基础层面有助于建构关键的交互假设和分析假设。

主要研究包括对实验室主任、临床微生物学家、采购负责人和行业高管进行结构化访谈，以了解营运实践、采购驱动因素和供应商绩效认知。这些访谈旨在探讨验证实务、试剂处理、工作流程限制和售后服务期望。访谈内容经过编码和综合分析，以识别反覆出现的主题、区域差异和营运痛点，并最终提出切实可行的建议。

透过交叉验证，对定量和定性输入资料进行三角检验，以确保资料的一致性并识别异常值。调查方法品管包括可重复性检查、分析师同行评审以及记录资料来源的审核追踪。这种混合方法有助于得出可靠的结论，并为临床、研究和商业相关人员提供切实可行的指导。

简明扼要的结论总结了指导永续药敏试验推广和临床整合的技术、操作和监管方面的必要条件。

总之，抗菌药物敏感性检测正从一项独立的实验室活动发展成为一项综合性的临床资源，为快速治疗决策、倡议计划和转化研究提供支持。技术进步，特别是自动化、分子混合工作流程和软体驱动报告的进步，在提高效率和临床价值的同时，也为验证、采购和供应链管理带来了复杂性。相关人员必须谨慎权衡这些利弊，在速度、准确性和营运可行性之间取得平衡。

监管动态、区域製造业趋势和不断变化的贸易政策，都为采购、服务模式和供应商选择增添了许多策略考量。成功的企业将投资于可互通的平台，维持多元化的供应关係，将数据分析融入临床工作流程，并展现出可衡量的影响。临床、实验室和商业部门之间的协作对于将技术可能性转化为可靠的日常实践至关重要。

最终，务实的实验、严格的检验以及与最终用户的持续互动，对于确保易感性检测的创新能够改善患者预后并加强公共卫生准备至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用微流体晶片技术扩大即时快速敏感度检测的规模
  • 利用人工智慧驱动的解释演算法来提高抗菌药物敏感性试验结果的准确性
  • 抗菌药物管理计划日益重要，推动了对快速抗菌药物敏感性试验解决方案的需求。
  • 自动化、高通量表型易感性检测设备的商业化
  • 新型抗生素敏感性检测生物标记和检测方法的监管核准
  • 将即时云端基础数据分析整合到临床抗菌药物敏感性试验（AST）工作流程中，以支援决策。
  • 开发可携式多路復用AST设备
  • 加大对基于次世代定序的抗药性分析在临床诊断上的投资

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 人类抗菌药物敏感性测试市场（依产品分类）

  • 装置
    • 工作台
    • WalkAway
  • 试剂耗材
    • 磁碟
    • 套件
    • 媒体
    • 条
  • 软体

9. 按技术分類的人类抗菌药物敏感性检测市场

  • 自动化系统
    • 微型扫描系统
    • 凤凰系统
    • Vitec Systems
  • 盘状扩散
  • 渐变条
  • 微量稀释法
  • 分子方法

10. 按检测类型分類的人类抗菌药物敏感性检测市场

  • 自动化测试
  • 手动测试
    • 琼脂稀释法
    • 肉汤微量稀释法
    • 盘状扩散
    • 渐变条

第十一章：按应用分類的人类抗菌药物敏感性测试市场

  • 临床诊断
  • 製药
  • 研究

12. 按最终用户分類的人类抗菌药物敏感性测试市场

  • 诊所
  • 诊断实验室
  • 医院
  • 研究所

13. 依病原体分類的人类抗菌药物敏感性检测市场

  • 真菌
  • 革兰氏阴性菌
    • 肠桿菌科
    • 除肠桿菌科以外的细菌
  • 革兰氏阳性菌
  • 抗酸桿菌

14. 各地区人类抗菌药物敏感性检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 按组别分類的人类抗菌药物敏感性检测市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国人类抗菌药物敏感性检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • Danaher Corporation
    • Siemens Healthineers AG
    • Accelerate Diagnostics Inc.
    • Bruker Corporation
    • QIAGEN NV
    • F. Hoffmann-La Roche AG
    • Luminex Corporation
Product Code: MRR-4E27A4DF1227

The Human Antimicrobial Susceptibility Testing Market is projected to grow by USD 6.30 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.92 billion
Estimated Year [2025] USD 4.16 billion
Forecast Year [2032] USD 6.30 billion
CAGR (%) 6.10%

High-impact introduction outlining the converging clinical, operational, and technological forces reshaping antimicrobial susceptibility testing practices globally

The landscape of human antimicrobial susceptibility testing is at an inflection point driven by converging clinical pressures, evolving laboratory workflows, and accelerating technology maturation. Clinical teams confront increasing diagnostic complexity as polymicrobial infections, resistance mechanisms, and the need for rapid actionable results demand both robustness and speed in susceptibility outputs. At the same time, research and pharmaceutical partners are intensifying their demand for standardized, reproducible testing platforms that can integrate with drug development pipelines and translational studies.

Laboratories face competing priorities: maintaining regulatory compliance, reducing turnaround times, and optimizing reagent and instrument utilization while managing constrained budgets and skilled workforce shortages. These operational realities are reshaping procurement criteria, shifting the emphasis toward systems that deliver automation, connectivity, and validated performance across diverse specimen types. The introduction of advanced molecular and phenotypic hybrid workflows is redefining the role of AST as a bridge between identification and therapeutic stewardship.

Given these pressures, stakeholders must reconcile near-term clinical imperatives with long-term strategic investments. Cross-functional collaboration among clinicians, microbiologists, informaticians, and procurement teams is essential to translate diagnostic intelligence into improved patient outcomes. This introduction establishes the critical context and the main vectors of change that inform the deeper analysis in subsequent sections

Defining transformative technological and commercial shifts that are accelerating automation, molecular hybridization, and software integration across susceptibility testing workflows

The field of antimicrobial susceptibility testing is undergoing transformative shifts driven by automation, molecular integration, and software-enabled decision support. Automated systems are progressively reducing manual hands-on time and variability, enabling laboratories to scale capacity without proportionally expanding headcount. This transformation is reinforced by software platforms that consolidate results, enable trend analysis, and provide stewardship-focused reporting-shifting AST from a standalone laboratory procedure to an integral part of clinical decision pathways.

Parallel advances in molecular methods are enabling targeted detection of resistance determinants that complement phenotypic susceptibility outputs. Hybrid workflows that combine rapid molecular screening with confirmatory phenotypic testing are emerging as pragmatic solutions that balance speed and clinical relevance. Additionally, reagent and consumable innovations-such as pre-formulated media, stabilized strips, and kit-based reagents-are simplifying routine workflows and improving reproducibility across decentralized testing environments.

These shifts are also catalyzing changes in commercial strategy: vendors are prioritizing interoperable platforms, open data standards, and service models that extend beyond capital sales into consumable-based and data-driven revenue streams. As a result, clinical laboratories and research organizations must adapt procurement, validation, and IT integration approaches to fully realize the potential of these transformative technologies

Assessing the cumulative operational and supply chain consequences of United States tariff changes implemented in 2025 on testing procurement and laboratory continuity

The introduction of tariff measures and trade policy adjustments in 2025 has created complex downstream effects for laboratories, manufacturers, and distribution networks involved in antimicrobial susceptibility testing. Increased import duties and regulatory friction on key imported instruments, reagents, and components have amplified procurement lead times and prompted procurement teams to reassess total landed costs. As a consequence, supply chain planning has moved from periodic purchasing toward continuous risk mitigation and multi-sourcing strategies.

Manufacturers have responded by reassessing their global manufacturing footprints, increasing local production in tariff-affected jurisdictions, and reconfiguring supply networks to mitigate cost volatility. These shifts have altered decisions about inventory buffering, strategic stockpiling of critical consumables, and contractual terms with distributors. For laboratories, the practical implications include extended validation timelines for newly sourced products, potential substitutions that require cross-validation, and closer scrutiny of vendor service models to ensure continuity in testing capabilities during transition periods.

Looking ahead, sustained tariff-driven disruption can incentivize regional supply resilience and spur investments in domestic reagent and instrument production. At the same time, stakeholders must monitor regulatory harmonization efforts and trade negotiations that could ease friction. In this environment, flexible procurement strategies, enhanced supplier collaboration, and forward-looking validation protocols will be essential to preserve testing continuity and clinical reliability

Integrated segmentation insights linking product, technology, test type, application, end-user, and pathogen dimensions to practical procurement and validation imperatives

A nuanced segmentation framework reveals where clinical need, technological capability, and procurement behavior intersect across product, technology, test type, application, end user, and pathogen dimensions. Product differentiation encompasses instruments, reagents and consumables, and software, with instruments subdivided by bench top and walk-away modalities and reagents and consumables including discs, kits, media, and strips-each category driving distinct validation, inventory, and cost considerations for laboratories. This product-level granularity informs procurement priorities: bench top platforms often emphasize local footprint and flexibility, whereas walk-away systems prioritize throughput and integration.

Technology segmentation spans automated systems, disk diffusion, gradient strip, microdilution, and molecular methods; within automation, platform-level differentiation between MicroScan-style, Phoenix-style, and fully integrated Vitek-style systems determines interoperability and laboratory workflow redesign. Test type distinctions between automated testing and manual testing-where manual approaches include agar dilution, broth microdilution, disk diffusion, and gradient strip-highlight trade-offs between analytical precision and operational scalability. Applications range from clinical diagnostics to pharmaceutical development and research, with each use case imposing unique demands on validation rigor, traceability, and data integration.

End users such as clinics, diagnostic laboratories, hospitals, and research institutes each face different throughput profiles, capital constraints, and regulatory expectations, which influence adoption curves across the product and technology spectrum. Pathogen classification across fungi, gram negative bacteria, gram positive bacteria, and mycobacteria-along with finer distinctions such as Enterobacteriaceae versus non-Enterobacteriaceae within gram negatives-shapes reagent formulation needs, interpretive criteria, and susceptibility endpoint determination. Understanding these interdependent segmentation layers enables stakeholders to prioritize investments and tailor operational roadmaps

Critical regional insights revealing how regulatory frameworks, infrastructure investment, and manufacturing dynamics are shaping adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics are reshaping procurement preferences, regulatory interaction, and innovation diffusion across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a strong emphasis on rapid diagnostics and consolidation of centralized testing networks is driving demand for high-throughput automated platforms and integrated informatics that support stewardship initiatives. Laboratories in this region are increasingly focused on rapid turnaround and scalability to manage complex caseloads, which influences choices in instruments and consumables.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory harmonization efforts, public health priorities, and fiscal constraints create diverse adoption patterns. In parts of this geography, stringent regulatory pathways and centralized procurement models favor validated, standardized solutions; in other areas, decentralized laboratories prioritize cost-effective manual methods and localized reagent solutions. Asia-Pacific demonstrates rapid adoption of automation and molecular hybrid approaches, supported by expanding domestic manufacturing capabilities and strong investment in laboratory infrastructure. This region's scale and manufacturing density also make it a focal point for supply chain reconfiguration and reagent localization efforts.

Across all regions, local regulatory frameworks, reimbursement models, and workforce availability will continue to moderate adoption rates and shape vendor strategies. A clear understanding of regional priorities is essential for tailoring market entry, service models, and distribution partnerships that align with local laboratory operations and clinical governance

Analyzing vendor strategies that prioritize interoperability, consumable-based service models, and regulatory compliance to strengthen clinical and commercial positioning

Leading companies in the antimicrobial susceptibility testing ecosystem are increasingly oriented toward platform interoperability, consumable-driven service models, and data analytics that support clinical decision-making and antimicrobial stewardship objectives. Vendors are enhancing their value propositions by integrating laboratory information systems connectivity, automating interpretive reporting, and offering lifecycle services that reduce the validation burden on end users. These strategic moves prioritize long-term partnerships with clinical networks over single-transaction equipment sales.

Competitive differentiation is also emerging through reagent innovation, such as stabilized kits and simplified media formulations that reduce variability and improve shelf stability across diverse laboratory environments. Manufacturers are investing in modular systems that enable incremental upgrades, protecting capital investments while offering pathways to higher throughput and expanded test menus. Strategic alliances between instrument providers and molecular assay developers are accelerating hybrid workflows that can quickly translate resistance determinant detection into actionable susceptibility guidance.

Finally, companies are intensifying focus on regulatory compliance and localized support, recognizing that rapid service response and robust post-market surveillance are critical for clinical trust. This combination of product innovation, service orientation, and regulatory rigor defines the competitive contours of the market and informs procurement and partnership choices by hospitals, reference laboratories, and research organizations

Actionable strategic recommendations for vendors and laboratories to enhance resilience, interoperability, and clinical impact across susceptibility testing operations

Industry leaders should pursue a balanced strategy that advances automation and molecular integration while preserving flexibility for manual and decentralized testing contexts. Prioritizing investments in modular, interoperable platforms will allow laboratories to scale capabilities without committing to prohibitive capital outlays. Concurrently, establishing robust partnerships with regional reagent manufacturers and distributors will enhance supply resilience and reduce dependency on single-source supply chains.

Operationally, embedding data analytics and stewardship-oriented reporting into platform design will increase clinical impact and support hospital governance objectives. Vendors and laboratories alike should collaborate to standardize data formats and adopt APIs that facilitate integration with electronic health records and infection control systems. From a regulatory and quality perspective, accelerating validation pipelines through pre-approved protocols and harmonized method comparison studies will reduce time to deployment and ensure consistent performance across diverse settings.

Finally, stakeholders should adopt dynamic procurement approaches that incorporate total cost of ownership, service responsiveness, and validation burden into purchasing decisions. By aligning commercial models with clinical workflows and long-term support commitments, industry leaders can unlock sustainable adoption and improved patient outcomes while mitigating operational and supply chain disruptions

Transparent mixed-methods research approach combining literature synthesis, primary stakeholder interviews, and cross-validated data triangulation to ensure analytical rigor

The research methodology combines systematic secondary evidence gathering, targeted primary engagement, and rigorous data triangulation to ensure robust and reproducible insights. Secondary work included a structured review of peer-reviewed literature, regulatory guidance documents, technical white papers, and public procurement policies to establish a factual baseline for technology capabilities, testing standards, and regulatory expectations. This foundational layer informed the design of primary interactions and the framing of analytical hypotheses.

Primary research incorporated structured interviews with laboratory directors, clinical microbiologists, procurement officers, and industry executives to capture operational realities, procurement drivers, and vendor performance perceptions. These engagements were designed to probe validation practices, reagent handling, workflow constraints, and post-market service expectations. Responses were coded and synthesized to identify recurring themes, regional differentiators, and operational pain points that inform practical recommendations.

Quantitative and qualitative inputs were triangulated through cross-validation across data sources, ensuring consistency and identifying outliers. Methodological quality controls included reproducibility checks, analyst peer review, and an audit trail documenting source provenance. This mixed-methods approach supports defensible conclusions and actionable guidance tailored to clinical, research, and commercial stakeholders

Concise conclusion synthesizing technological, operational, and regulatory imperatives to guide sustainable adoption and clinical integration of susceptibility testing

In conclusion, antimicrobial susceptibility testing is evolving from a discrete laboratory task into an integrated clinical asset that supports rapid therapeutic decision-making, stewardship initiatives, and translational research. Technological advances-particularly in automation, molecular hybrid workflows, and software-enabled reporting-are unlocking new efficiencies and clinical value, while also introducing complexity in validation, procurement, and supply chain management. Stakeholders must navigate these trade-offs deliberately, balancing speed, accuracy, and operational feasibility.

Regulatory dynamics, regional manufacturing trends, and trade policy shifts add layers of strategic consideration that influence procurement, service models, and vendor selection. Successful organizations will be those that invest in interoperable platforms, maintain diversified supply relationships, and embed data analytics into clinical workflows to demonstrate measurable impact. Collaboration across clinical, laboratory, and commercial functions will be essential to translate technological potential into reliable, everyday practice.

Ultimately, the path forward requires pragmatic experimentation, rigorous validation, and sustained engagement with end users to ensure that innovations in susceptibility testing deliver improved patient outcomes and enhanced public health preparedness

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of point-of-care rapid susceptibility testing using microfluidic chip technology
  • 5.2. Adoption of AI-driven interpretive algorithms to enhance antimicrobial susceptibility result accuracy
  • 5.3. Growing emphasis on antimicrobial stewardship programs driving demand for rapid AST solutions
  • 5.4. Commercialization of automated high-throughput phenotypic susceptibility testing instruments
  • 5.5. Regulatory approvals for novel antibiotic susceptibility testing biomarkers and assays
  • 5.6. Integration of real-time cloud-based data analytics in clinical AST workflow for decision support
  • 5.7. Development of portable multiplexed AST devices for remote and decentralized healthcare settings
  • 5.8. Rising investment in next-generation sequencing-based resistance profiling for clinical diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Antimicrobial Susceptibility Testing Market, by Product

  • 8.1. Instruments
    • 8.1.1. Bench Top
    • 8.1.2. Walk Away
  • 8.2. Reagents Consumables
    • 8.2.1. Discs
    • 8.2.2. Kits
    • 8.2.3. Media
    • 8.2.4. Strips
  • 8.3. Software

9. Human Antimicrobial Susceptibility Testing Market, by Technology

  • 9.1. Automated Systems
    • 9.1.1. MicroScan Systems
    • 9.1.2. Phoenix Systems
    • 9.1.3. Vitek Systems
  • 9.2. Disk Diffusion
  • 9.3. Gradient Strip
  • 9.4. Microdilution
  • 9.5. Molecular Methods

10. Human Antimicrobial Susceptibility Testing Market, by Test Type

  • 10.1. Automated Testing
  • 10.2. Manual Testing
    • 10.2.1. Agar Dilution
    • 10.2.2. Broth Microdilution
    • 10.2.3. Disk Diffusion
    • 10.2.4. Gradient Strip

11. Human Antimicrobial Susceptibility Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Pharmaceutical
  • 11.3. Research

12. Human Antimicrobial Susceptibility Testing Market, by End User

  • 12.1. Clinics
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Human Antimicrobial Susceptibility Testing Market, by Pathogen

  • 13.1. Fungi
  • 13.2. Gram Negative Bacteria
    • 13.2.1. Enterobacteriaceae
    • 13.2.2. Non Enterobacteriaceae
  • 13.3. Gram Positive Bacteria
  • 13.4. Mycobacteria

14. Human Antimicrobial Susceptibility Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Antimicrobial Susceptibility Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Antimicrobial Susceptibility Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. bioMerieux SA
    • 17.3.2. Thermo Fisher Scientific Inc.
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. Danaher Corporation
    • 17.3.5. Siemens Healthineers AG
    • 17.3.6. Accelerate Diagnostics Inc.
    • 17.3.7. Bruker Corporation
    • 17.3.8. QIAGEN N.V.
    • 17.3.9. F. Hoffmann-La Roche AG
    • 17.3.10. Luminex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)